Goldman Sachs analyst Patrick Donnelly upgraded Exact Sciences to Buy and raised his price target for the shares to $120 from $85. The stock closed yesterday down 28c to $91.76. The ramp of Cologuard remains in the early stages with acceleration ahead, and Exact’s pipeline optionality is underappreciated, Donnelly tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.